Hao Zeng

west china medical school

H指数:27

被引数:3,622

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fumarate activates the IL-6/JAK/STAT3 pathway by inhibiting KDM4C-mediated H3K36me3 demethylation in FH-knockdown renal cancer cells

富马酸通过抑制KDM4C介导的H3K36me3去甲基化，激活IL-6/JAK/STAT3通路，在FH-knockdown肾癌细胞中发挥作用。

British Journal of Cancer

IF6.8

2025-09-200

PRE

First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trials

晚期或局部晚期尿路上皮癌患者的一线系统性治疗：一项随机对照试验的系统评价和网络Meta分析

Therapeutic Advances in Medical Oncology

IF4.2

2025-07-230

Real-time ATP monitoring revolutionizing wastewater treatment: Improving effluent quality prediction based on microbial activity

实时ATP监测正在革新废水处理：基于微生物活性改善出水水质预测

Process Safety and Environmental Protection

IF7.8

2025-07-180

PRE

Investigation on the strength enhancement mechanisms of C-S-H seeds on PC-CSA binders

C-S-H晶种对PC-CSA胶凝材料的强度增强机制研究

Journal of Building Engineering

IF7.4

2025-06-260

PRE

Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer

通过理性联合增强PARP抑制：PARP抑制剂的机制及其联合应用，重点关注转移性去势抵抗性前列腺癌的治疗

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

IF5.6

2025-06-011

PRE

Synergistic Bio-Organic Fertilization Enhances Tobacco Antioxidative Defense and Soil Health for Sustainable Agriculture

协同生物有机施肥增强烟草抗氧化防御和土壤健康，以实现可持续农业

ACS OMEGA

IF4.3

2025-05-080

Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinoma

有和没有导管腺癌的前列腺癌患者的液体活检的基因组特征

JOURNAL OF PATHOLOGY CLINICAL RESEARCH

IF3.7

2025-05-010

OAAI

Exposure to polycyclic aromatic hydrocarbons and bone mineral density in children and adolescents: results from the 2011-2016 National Health and Nutrition Examination Survey

接触多环芳烃与儿童和青少年骨密度：2011-2016年国家健康与营养调查结果

FRONTIERS IN PUBLIC HEALTH

IF3.4

2025-04-170

Metabolic tumor parameters on 18F-FDG PET/CT can predict the expression of PD-L1 and prognosis in patients with fumarate hydratase-deficient renal cell carcinoma

18F-FDG PET/CT的代谢肿瘤参数可预测富马酸水合酶缺陷型肾细胞癌患者中PD-L1的表达和预后

ANNALS OF NUCLEAR MEDICINE

IF2.5

2025-03-150

PRE

Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents

促性腺激素释放激素受体激动剂与拮抗剂在前列腺癌中的应用：对长期生存的影响及与新一代内分泌治疗药物的联合治疗

CANCER BIOLOGY & MEDICINE

IF8.4

2024-12-240

OAAI

UFO registry: final analysis of baseline data from patients with advanced prostate cancer in Asia

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2024-11-230

OAAI

Ultrasound-Driven Nanomachine for Enhanced Sonodynamic Therapy of Non-Small-Cell Lung Cancer

超声驱动的纳米机器用于非小细胞肺癌的增强声动力治疗

ACS APPLIED MATERIALS & INTERFACES

IF8.2

2024-10-220

PRE

Trajectory-centric framework TrajAtlas reveals multi-scale differentiation heterogeneity among cells, genes, and gene modules in osteogenesis

PLOS GENETICS

IF3.7

2024-10-220

OAAI

Phase III study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort

Talazoparib (TALA) 联合 Enzalutamide (ENZA) 与 Placebo (PBO) 联合 ENZA 作为转移性去势抵抗性前列腺癌 (mCRPC) 患者的一线 (1L) 治疗的 III 期研究：TALAPRO-2 (TP-2) 中国队列

ANNALS OF ONCOLOGY

IF65.4

2024-09-010

PRE

Targeted Reprogramming of Pathogenic Fibroblast Genes at the 3′-Untranslated Regions by DNA Nanorobots for Periodontitis

ACS NANO

IF16

2024-08-070

PRE

Comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT in Fumarate Hydratase-Deficient Renal Cell Carcinoma A Prospective and Single-Center Study

CLINICAL NUCLEAR MEDICINE

IF9.6

2024-07-030

PRE

Comparison of mechanical strengths and microstructure of Portland cement-calcium sulfoaluminate cement binders with cellulose ethers of different viscosities

硅酸盐水泥-硫铝酸钙水泥粘结剂与不同粘度纤维素醚的力学强度和微观结构比较

CONSTRUCTION AND BUILDING MATERIALS

IF8

2024-07-013

PRE

NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion

MOLECULAR CANCER RESEARCH

IF4.7

2024-07-010

Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma

在TFE3-rearranged肾细胞癌中，ASPSCR1-TFE3融合患者对基于ICI的联合治疗有更好的反应

MOLECULAR CANCER

IF33.9

2024-06-260

OAAI

The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis

BMC CANCER

IF3.4

2024-06-083

OAAI

Hao Zeng

个人简介

教育背景

工作经历

荣誉奖项

研究方向